Full-Time

Technical Advisor

Posted on 9/23/2025

Sotera Health

Sotera Health

1,001-5,000 employees

Outsourced sterilization and lab testing provider.

Compensation Overview

$87.5k - $142k/yr

Western Springs, IL, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • University Degree in Science field such as Chemistry, Chemical Engineering, Microbiology, or other related technical discipline
  • 6 years minimum experience in sterilization processing and sterility assurance of medical/pharma products
  • Thorough knowledge and minimum six years’ experience in sterilization processing and applicable regulatory standards
  • Strong influencing, leadership and facilitation skills
  • Excellent communication skills on all levels, including ability to communicate complex technical data to non-technical staff
  • Any additional relevant scientific experience
Responsibilities
  • Provide technical support to customers, facilities, operations, sales and laboratory.
  • Provide comprehensive consulting to customers in areas of expertise related to sterile processing and testing of products during the product’s entire life cycle.
  • Ensure proper validation of the products being processed.
  • Mentor Validation and Scientific personnel both formally and informally, to help them provide consistent project management, customer service and reports to customers.
  • Actively build professional network and participate in industry interactions, including standards committees and industry technical committees. Provide leadership in areas of expertise.
  • Help ensure compliance with all relevant regulations relating to sterilization.
  • Coordinate, review, report, and present technical data internally, to customers, trade associations and regulators.
  • Provide technical support in customer and regulatory audits.
  • Perform internal and external training in sterile processing.
  • Support R&D and New Technologies in sterilization projects.

Sotera Health provides sterilization and lab testing services to ensure the safety of medical devices, pharmaceuticals, and food products. The company operates through three divisions: Sterigenics, which uses methods like Gamma and X-ray to eliminate contaminants; Nordion, which supplies the Cobalt-60 isotopes needed for irradiation; and Nelson Labs, which performs over 800 microbiological and analytical tests. Unlike many competitors, it offers a fully integrated supply chain by producing its own sterilization sources while maintaining a global network of 63 facilities and labs. Its goal is to protect global health by providing the mission-critical services required to bring safe healthcare products to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Broadview Heights, Ohio

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Sterigenics volumes grew 8% in 2025, driving mid-to-high single-digit growth.
  • Q1 2026 operating margin hit 28.2%, up from 22.4%, via pricing power.
  • Sessa Capital bought $175.8M stake in February 2026, signaling investor confidence.

What critics are saying

  • EPA EtO enforcement and California bans constrain Sterigenics capacity by 2027.
  • Q1 2026 free cash flow plunged to negative $16.73M from $35.6M prior year.
  • Nelson Labs underperforms with low-single-digit growth versus Sterigenics' 8% volumes.

What makes Sotera Health unique

  • Sotera Health integrates Sterigenics, Nordion, and Nelson Labs for end-to-end sterilization and testing.
  • Nordion supplies Cobalt-60 with 70-year reliability for gamma irradiation worldwide.
  • Nelson Labs performs over 900 microbiological and analytical tests across 15 global labs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Education Assistance

Employee Assistance Program (EAP)

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Globe and Mail
Mar 24th, 2026
A $175 Million Move Into Sotera Health Signals Potential Opportunity Amid 21% Stock Drop

Detailed price information for Capital One Financial Corp (COF-N) from The Globe and Mail including charting and trades.

Intellectia.AI
Mar 23rd, 2026
Sessa Capital buys $175.8M stake in Sotera Health as shares outperform S&P 500

Sessa Capital has acquired an additional 10,630,381 shares of Sotera Health for approximately $175.80 million on 17 February 2026, bringing its quarter-end position value to $206.47 million. The transaction signals strong confidence in the healthcare services company. Sotera Health shares traded at $13.99 on Monday, representing an 18% gain over the past year, slightly outperforming the S&P 500's 15% increase. The company has generated revenue of approximately $1.16 billion and adjusted EBITDA near $600 million. Despite facing litigation and regulatory risks, Sotera Health's sustained growth potential continues attracting long-term investor interest. The substantial investment by Sessa Capital reinforces the company's position within the asset manager's portfolio.

Yahoo Finance
Mar 23rd, 2026
Sessa Capital invests $175M in Sotera Health following 21% stock drop

Sessa Capital purchased 10.63 million shares of Sotera Health in the fourth quarter for an estimated $175.80 million, according to a Securities and Exchange Commission filing dated 17 February. The stake now represents nearly 7% of Sessa Capital's reportable assets under management. Sotera Health provides sterilisation services and laboratory testing for medical device and pharmaceutical industries. The company generated $1.2 billion in revenue and $77.9 million in net income over the trailing twelve months. Despite 20 years of steady growth and adjusted EBITDA approaching $600 million, the stock has declined as investors focus on litigation risks, high leverage and regulatory concerns. The shares currently trade at $13.99, up 18% over the past year, with a market capitalisation of $4.0 billion.

Yahoo Finance
Mar 22nd, 2026
Sotera Health CFO reaffirms 5%–6.5% organic growth for 2026, eyes $500M–$600M free cash flow

Sotera Health's CFO Jon Lyons reaffirmed constant-currency organic growth guidance of 5% to 6.5% for 2026 at the KeyBanc Healthcare Forum. Sterigenics is expected to deliver mid- to high-single-digit growth, whilst Nordion and Nelson Labs will see lower-single-digit growth. The company closed 2025 with 5.2% organic revenue growth, maintaining over 50% EBITDA margins with a 118-basis-point improvement. Weaker Nelson Labs results were offset by stronger Sterigenics volumes of approximately 8%. Management prioritises free cash flow and capital discipline, targeting $500 million to $600 million over three years. Capital expenditure is expected to drop significantly in 2027 as projects complete. Net leverage has improved towards the 2x–3x target, providing flexibility for debt reduction, acquisitions or share buybacks.

Yahoo Finance
Mar 2nd, 2026
Sotera Health up 30% in a year as fund trims $3.6M stake but maintains conviction

Ananym Capital Management sold 217,684 shares of Sotera Health for an estimated $3.60 million in February 2026, according to an SEC filing. Despite the sale, Sotera Health remains a significant holding at 8.65% of Ananym's assets under management. Sotera Health shares were trading at $17.09 as of 17 February 2026, up nearly 30% over the past year and outperforming the S&P 500 by 14.86 percentage points. The company provides sterilisation services and laboratory testing for medical device, pharmaceutical and food industries. Sotera recently reported its 20th consecutive year of revenue growth, with 2025 revenues rising nearly 6% to $1.16 billion. Management has guided for another 5% to 6.5% revenue increase in 2026, with adjusted EBITDA growth of 5.5% to 7%.

INACTIVE